Skip to main content
SpringerLink
Log in

Treatment of Patients with Essential Hypertension and Microalbuminuria

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

There has been increasing interest in the question of whether microalbuminuria can be used in the risk stratification of patients with essential hypertension. A cluster of cardiovascular and/or renal risk factors may be associated with microalbuminuria in hypertension. Despite this, prospective data about the potential role of microalbuminuria as a prognostic marker of cardiovascular and/or renal risk have been sparse and inconclusive until now.

Blood pressure values have been considered the most important determinant of microalbuminuria in essential hypertension; however, hyperinsulinaemia — a metabolic component — was noted to be present in conjunction with high blood pressure. Furthermore, 2 other factors may be also related to microalbuminuria: salt sensitivity and renal structural changes (nephrosclerosis). We are now aware that the clinical and physiological implications of abnormal urinary albumin excretion (UAE) are much broader than anticipated, possibly involving haemodynamic, metabolic and vascular components overlapping several clinical syndromes.

Achievement of short term UAE reduction with antihypertensive treatment depends on structural abnormalities established in the glomerulus, the extent of blood pressure reduction and the antihypertensive drug class used. In terms of UAE reduction, better results are obtained with ACE inhibitors or angiotensin II antagonists such as losartan and valsartan, than with other antihypertensive classes, although their true impact in preserving renal function needs to be assessed. The capacity of new calcium antagonists, such as amlodipine, lacidipine or mibefradil, to reduce UAE also needs to be assessed further.

Thus, microalbuminuria may be seen as an integrated marker of risk and should be assessed in recently diagnosed patients with essential hypertension. In microalbuminuric patients, the target should be to decrease blood pressure <135/85mm Hg, reduce salt intake to around 100 mmol/day and prescribe a low-calorie diet if obesity is present. ACE inhibitors or angiotensin II antagonists have more potential benefits than the other classes of antihypertensive drugs in reducing UAE. Finally, a yearly assessment of microalbuminuria is recommended during treatment, to monitor the impact of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356–60

    Article  PubMed  CAS  Google Scholar 

  2. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31: 673–89

    Article  PubMed  CAS  Google Scholar 

  3. Deckert T, Koford-Enevoldsen A, Norgaard K, et al. Microalbuminuria: implications for micro- and macrovascular disease. Diabetes Care 1992; 15: 1181–91

    Article  PubMed  CAS  Google Scholar 

  4. Damsgaard EM, Froland A, Jorgensen OD, et al. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297–300

    Article  PubMed  CAS  Google Scholar 

  5. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects: Islington diabetes survey. Lancet 1988; II: 530–3

    Article  Google Scholar 

  6. Kuusisto J, Mykkänen L, Pyörälä K, et al. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 1995; 91: 831–7

    Article  PubMed  CAS  Google Scholar 

  7. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease: I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 325: 765–74

    Article  Google Scholar 

  8. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8

    Article  PubMed  CAS  Google Scholar 

  9. Parving HH, Jensen H, Mogensen CE, et al. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; I: 1190–2

    Article  Google Scholar 

  10. Redon J, Pascual JM, Miralies A, et al. Microalbuminuria in essential hypertension [in Spanish]. Med Clin 1991; 96: 525–9

    CAS  Google Scholar 

  11. Bianchi S, Bigazzi R, Valtriani C, et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23 Pt 1: 681–7

    Article  PubMed  CAS  Google Scholar 

  12. Redon J, Miralles A, Pascual JM, et al. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15: 79–86

    Article  PubMed  CAS  Google Scholar 

  13. Cerasola G, Cottone S, D’Ignoto G, et al. Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989; 7Suppl. 6: S332–3

    CAS  Google Scholar 

  14. Giaconi S, Levanti C, Fommei E, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens 1989; 2: 259–61

    PubMed  CAS  Google Scholar 

  15. Bigazzi R, Bianchi S, Nenci R, et al. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9: 827–33

    PubMed  CAS  Google Scholar 

  16. Del Sette A, Zagami P, Angeli S, et al. Carotid diameter, wall thickness, and parietal stress in essential hypertension [abstract]. Stroke 1995; 26: 2373

    PubMed  Google Scholar 

  17. Agrawal B, Berger A, Wolf K, et al. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223–8

    Article  PubMed  CAS  Google Scholar 

  18. Palatini P, Graniero GR, Mormino P, et al. Prevalence and clinical correlates of microalbuminuria in stage I hypertension: results from the hypertension and ambulatory recording Venetia study (HARVEST study). Am J Hypertens 1996; 9: 334–41

    Article  PubMed  CAS  Google Scholar 

  19. Agewall S, Wikstrand J, Ljungman S, et al. Does microalbuminuria predict cardiovascular events in nondiabetic men with treated hypertension? Am J Hypertens 1995; 8: 337–42

    Article  PubMed  CAS  Google Scholar 

  20. Bianchi S, Bigazzi R, Campese VM. Increased cardiovascular events in patients with hypertension and microalbuminuria [abstract]. J Am Soc Nephrol 1996; 7: 1546

    Google Scholar 

  21. Ljungman S, Wikstrand J, Hartford M, et al. Urinary albumin excretion — a predictor of risk of cardiovascular disease: a prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9: 770–8

    Article  PubMed  CAS  Google Scholar 

  22. Schmieder RE. Predictors for hypertensive nephropathy: results of a 6-year follow-up study in essential hypertension. J Hypertens 1994; 13: 357–65

    Google Scholar 

  23. Halimi JM, Ribstein J, Du Cailar G, et al. Albuminuria predicts renal functional outcomes after intervention in atheromatous renovascular disease. J Hypertens 1995; 13: 1335–42

    Article  PubMed  CAS  Google Scholar 

  24. Redon J, Lozano JV, Liao Y, et al. Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 801–7

    PubMed  CAS  Google Scholar 

  25. Opsahl JA, Abraham PA, Haltenson ChE, et al. Correlation of office and ambulatory blood pressure measurements with urinary albumin and N-acetyl-β-D-glucosaminidase excretion in essential hypertension. Am J Hypertens 1988; 1: 117S–20S

    PubMed  CAS  Google Scholar 

  26. Gerber LM, Smukler C, Alderman MH. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch Intern Med 1992; 152: 373–7

    Article  PubMed  CAS  Google Scholar 

  27. Bigazzi R, Bianchi S, Campese VM, et al. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61: 94–7

    Article  PubMed  CAS  Google Scholar 

  28. Cottone S, Controno A, D’Ignoto G, et al. Prevalence of microalbuminuria in essential hypertension [abstract]. Am J Hypertens 1993; 6: 30A

    Google Scholar 

  29. Redon J, Gomez-Sanchez MA, Baldo E, et al. Microalbuminuria correlates with left ventricular hypertrophy in male hypertensive patients. J Hypertens 1991; 9Suppl. 6: S148–9

    CAS  Google Scholar 

  30. Lurbe E, Redon J, Pascual JM, et al. Altered blood pressure during sleep in normotensive subjects with type 1 diabetes. Hypertension 1993; 21: 227–35

    Article  PubMed  CAS  Google Scholar 

  31. Agewall S, Personi B, Samuelsson O, et al. Microalbuminuria in treated hypertensive men at high risk of coronary disease. J Hypertens 1993; 11: 461–9

    Article  PubMed  CAS  Google Scholar 

  32. Agewall S, Fagerberg B, Attvall S, et al. Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. J Intern Med 1995; 237: 195–203

    Article  PubMed  CAS  Google Scholar 

  33. Haffner SM, Stern MP, Kozlowski MK, et al. Microalbuminuria: potential marker for increased cardiovascular risk factors in nondiabetic subjects?. Arteriosclerosis 1990; 10: 727–31

    Article  PubMed  CAS  Google Scholar 

  34. Bianchi S, Bigazzi R, Qiñones A, et al. Insulin resistance in microalbuminuric hypertension: sites and mechanisms. Hypertension 1995; 26: 789–95

    Article  PubMed  CAS  Google Scholar 

  35. Kwiterovich PO. Genetics and molecular biology of familial combined hyperlipidemia. Curr Opin Lipidol 1993; 4: 113–43

    Article  Google Scholar 

  36. Hilsted J, Christensen NJ. Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia 1992; 35: 99–103

    Article  PubMed  CAS  Google Scholar 

  37. Nosadini R, Semplicini A, Fioretto P, et al. Sodium-lithium countertransport and cardiorenal abnormalities in essential hypertension. Hypertension 1991; 18: 191–8

    Article  PubMed  CAS  Google Scholar 

  38. Erley CM, Risler T. Microalbuminuria in primary hypertension: is it a marker of glomerular damage? Nephrol Dial Transplant 1995; 9: 1713–5

    Google Scholar 

  39. Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension 1994; 23: 195–9

    Article  PubMed  CAS  Google Scholar 

  40. Nesovic M, Stojanovic M, Nesovic MM, et al. Microalbuminuria is associated with salt sensitivity in hypertensive patients. J Hum Hypertens 1996; 10: 573–6

    PubMed  CAS  Google Scholar 

  41. Erley CM, Holzer M, Kramer BK, et al. Renal hemodynamics and organ damage in young hypertensive patients with different plasma renin activities after ACE inhibition. Nephrol Dial Transplant 1992; 7: 216–20

    PubMed  CAS  Google Scholar 

  42. Pontremoli R, Bezante GP, Sofia A. Deletion polymorphism of the angiotensin I converting enzyme gene is a risk factor for target organ damage in essential hypertension [abstract]. J Am Soc Nephrol 1995; 3: 647

    Google Scholar 

  43. Campese VM. Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension 1994; 23: 531–50

    Article  PubMed  CAS  Google Scholar 

  44. Weir MR, Dengel DR, Behrens MT, et al. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25: 1339–44

    Article  PubMed  CAS  Google Scholar 

  45. Sommers SC, Melamed J. Renal pathology of essential hypertension. Am J Hypertens 1990; 3: 583–7

    PubMed  CAS  Google Scholar 

  46. Yoshioka T. ‘Intact nephrons’ as the primary origin of proteinuria in chronic renal diseases. Study in the rat model of subtotal nephrectomy. J Clin Invest 1988; 82: 1614–23

    Article  PubMed  CAS  Google Scholar 

  47. Christensen CK, Krusell LR. Acute and long-term effect of antihypertensive treatment on exercise induced microalbuminuria in essential hypertension. J Clin Hypertens 1987; 3: 704–12

    PubMed  CAS  Google Scholar 

  48. Biesenbach G, Zazgornik J. High prevalence of hypertensive retinopathy and coronary heart disease in hypertensive patients with persistent microalbuminuria under short intensive antihypertensive therapy. Clin Nephrol 1994; 41: 211–8

    PubMed  CAS  Google Scholar 

  49. Ruilope LM, Alcazar JM, Hernandez E, et al. Does an adequate control of blood pressure protect the kidney in essential hypertension?. J Hypertens 1990; 8: 525–31

    Article  PubMed  CAS  Google Scholar 

  50. Siewert-Delle A, Ljungman S, Hartford M, et al. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension: addition of felodipine or ramipril to long-term treatment with beta-blocker. Am J Hypertens 1995; 8: 113–23

    Article  PubMed  CAS  Google Scholar 

  51. Bianchi S, Bigazzi R, Baldari G, et al. Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. Am J Med 1992; 93: 525–8

    Article  PubMed  CAS  Google Scholar 

  52. Widecka K, Celiba R, Czekalski S. Comparison of treatment effects with an angiotensin converting enzyme inhibitor — lisinopril — and a calcium blocker — nifedipine retard — on urinary albumin excretion in patients with non-complicated essential hypertension [in Polish]. Pol Arch Med Wewn 1995; 93: 135–42

    PubMed  CAS  Google Scholar 

  53. Abate D, Cafaa R, Castellino AR, et al. Variations in microalbuminuria in essential hypertension treated with ACE inhibitors, calcium antagonists and their association [in Italian]. Minerva Cardioangiol 1995; 43: 303–7

    PubMed  CAS  Google Scholar 

  54. Alli C, Lombardo M, Zanni D, et al. Albuminuria and transferrinuria in essential hypertension: effects of antihypertensive therapy. Am J Hypertens 1996; 9: 1068–76

    Article  PubMed  CAS  Google Scholar 

  55. Cabezas-Cerrato J, Garcia-Estevez DA, Araujo D, et al. Insulin sensitivity, glucose effectiveness, and beta-cell function in obese males with essential hypertension: investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril). Metabolism 1997 Feb; 46: 173–8

    Article  PubMed  CAS  Google Scholar 

  56. Puig JG, Mateos FA, Ramos TH, et al. Albumin excretion rate and metabolic modifications in patients with essential hypertension: effect of two angiotensin converting enzyme inhibitors. Am J Hypertens 1994; 7: 46–51

    PubMed  CAS  Google Scholar 

  57. Larochell P. Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Am J Hypertens 1996; 9: 551–9

    Article  Google Scholar 

  58. Dominguez LJ, Barbagallo M, Kattah W, et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens 1995; 8: 808–14

    Article  PubMed  CAS  Google Scholar 

  59. Schmieder RE, Ruddel H, Schlebusch H, et al. Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. Am J Hypertens 1992 May; 5: 318–21

    PubMed  CAS  Google Scholar 

  60. Bignotti M, Lamponi M. Renal and cardiac effects of chronic doxazosin therapy in patients with essential arterial hypertension [in Italian]. Minerva Cardioangiol 1996; 44: 331–5

    PubMed  CAS  Google Scholar 

  61. Erley CM, Haefele U, Heyne N, et al. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension 1993; 21: 810–5

    Article  PubMed  CAS  Google Scholar 

  62. Ruilope LM, Alcazar JM, Hernandez E, et al. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 1994; 45Suppl. 45: S171–3

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Valencia, Spain

    Josep Redon

Authors
  1. Josep Redon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Redon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Redon, J. Treatment of Patients with Essential Hypertension and Microalbuminuria. Drugs 54, 857–866 (1997). https://doi.org/10.2165/00003495-199754060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199754060-00005

Keywords

Search

Navigation